

Flupirtine Analogues: Explorative Synthesis and Influence of Chemical Structure on $K_V7.2/K_V7.3$ Channel Opening Activity

Abdrrahman S. Surur,^[a] Kristin Beirow,^[a] Christian Bock,^[a] Lukas Schulig,^[a] Markus K. Kindermann,^[a] Anja Bodtke,^[a] Werner Siegmund,^[b] Patrick J. Bednarski,^[a] and Andreas Link^{*[a]}

Dedicated to Bernd Clement on the occasion of his 70th birthday and retirement as university professor

Neuronal voltage-gated potassium channels $K_V7.2/K_V7.3$ are sensitive to small-molecule drugs such as flupirtine, even though physiological response occurs in the absence of ligands. Clinically, prolonged use of flupirtine as a pain medication is associated with rare cases of drug-induced liver injury. Thus, safety concerns prevent a broader use of this non-opioid and non-steroidal analgesic in therapeutic areas with unmet medical needs such as hyperactive bladder or neonatal seizures. With the goal of studying influences of chemical structure on activity and toxicity of flupirtine, we explored modifications of the benzylamino bridge and the substitution pattern in both rings of flupirtine. Among twelve derivatives, four novel thioether derivatives showed the desired activity in cellular assays and may serve as leads for safer K_V channel openers.

Flupirtine (**1**) is a non-opioid and non-steroidal, centrally acting analgesic with a unique mode of action. The analgesic effect of **1** is believed to be associated with the opening of heterotetrameric voltage-gated potassium channels, consisting of the subunits $K_V7.2$ and $K_V7.3$, which are encoded by *KCNQ2* and *KCNQ3*, leading to membrane potential stabilization and decreased excitability.^[1] The $K_V7.2/K_V7.3$ channel generates M-currents that control the subthreshold excitability of the cell membrane, therefore, drugs that stabilize the open state of $K_V7.2/K_V7.3$ channels could be used in a broad range of CNS

diseases that are characterized by neuronal over-activity, including pain, stress, anxiety and epilepsy. While **1** is regarded safe in short-term use for acute pain, a recent clinical study provided indirect evidence that **1** can be oxidized in healthy volunteers to unstable *ortho*- or *para*-azaquinone diimines **3a** and/or **b** (Figure 1) as reactive metabolites.^[2] While neither




Figure 1. Structure of K_V channel openers **1** and **2**, elusive metabolites **3a** and **b**, product **4** of phase II drug metabolism, and direct thio-analogue **5** of **1** used for theoretical comparison in Figure 2 B).

compound **3a** nor **3b** could be identified directly, their formation was deduced from presence of cysteine metabolites in biological fluids,^[2] formed by reactions of the reactive intermediates with glutathione to yield adducts such as **4**. While it is not known whether reactive electrophiles **3a** or **3b** are the causative agent for drug-induced liver injury (DILI), safety issues lead to a termination of a clinical study with **1** in hyperactive bladder in 2013.^[3]

Although **1** was approved for use as a centrally acting analgesic in a number of European countries until 2018, it was not approved as an anticonvulsant. Two recent animal studies however have demonstrated that **1** terminates seizures in neonatal mammals effectively, and that a combination of **1** and diazepam is superior to diazepam alone.^[4] Because the closely-

[a] A. S. Surur, K. Beirow, C. Bock, L. Schulig, Dr. M. K. Kindermann, Dr. A. Bodtke, Prof. Dr. P. J. Bednarski, Prof. Dr. A. Link
Institute of Pharmacy
University of Greifswald
Friedrich-Ludwig-Jahn-Str. 17, 17489 Greifswald, Germany
Fax: (+49) (0)3834 864895
E-mail: link@uni-greifswald.de

[b] Prof. Dr. W. Siegmund
Center of Drug Absorption and Transport (C_DAT)
Greifswald

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/open.201800244>

©2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

related K_V channel opener retigabine (**2**) had been used as antiepileptic, until it was also withdrawn from the market in 2017, this additional indication for **1** would seem a logical endeavor. To date, treatment options for severe cases of status epilepticus are scarce.

Follow-up substance **2** marketed as Trobalt® has been taken of the market by GSK, last year. One of the main reasons was a blueish tissue discoloration.^[5] While the exact structure of the blue dye could not be resolved, it is most likely that the formation of polymers of **2** is the cause for this adverse effect. Based on earlier findings that **1** and its metabolites can only be traced to a limited extent in excretas, we speculate that diimines such as **3a** and **b** could form insoluble polymers *in vivo*, as well. This hypothesis is supported by the report, that DILI caused by **1** is not influenced by typical polymorphisms of metabolic enzymes but associated to Human leucocyte antigen (HLA) genotype.^[6] It seems possible, that polymerization *in vivo* triggers an immune response that could lead to the observed hepatotoxicity. Consequently, the search for flupirtine analogues with a better safety profile seems worthwhile.

The tendency of **1** to form **3a** or **3b** or polymers may be attributed to electronic features such as oxidation potentials. By calculating the molecular orbitals of flupirtine (Figure 2) one




Figure 2. A) HOMO of flupirtine (**1**); B) HOMO of equally active but putatively non-toxic lead **5**.

finds that the highest occupied molecular orbital (HOMO) and HOMO-1 are localized around the pyridine ring. This explains the oxidation susceptibility of the heterocyclic ring to form azaquinone diimine metabolites. The same calculation for deazathio-flupirtine **5** showed that the HOMO orbital will shift from pyridine to the sulfur atom. This flupirtine analogue **5** is equally active as **1** but non-toxic *in vitro* and was thus selected as a starting point for the synthesis of more potent flupirtine analogues.^[7] Our experiments on the oxidation of thio-analogues to sulfoxides with a stoichiometric equivalent of *m*-chloroperbenzoic acid also confirm this computational result. In order to alter these unfavorable electronic features of **1**, we synthesized flupirtine analogues with modifications that should avoid the formation of azaquinone diimines and polymers *in vivo*.

To plan the modifications of **1**, we divided its chemical structure into four regions; the 4-fluorobenzyl moiety, the secondary amine linker, the primary amine substituent, and the carbamate group. All analogues reported here have a sulfur containing functional group in place of the secondary amine linker. As shown in the HOMO calculation, the placement of this

Table 1. Residues R^1 – R^3 in intermediates **8a–h**, thioethers **9a–d,f–h** and thioester **9e**, and sulfoxides **10a–d**


Entry	R^1	R^2	R^3	Yield ^[a] [%]
8a	NH ₂	4-Fluorobenzyl		85
8b	NH ₂	4-Phenylbenzyl		90
8c	NH ₂	3,5-Dimethoxybenzyl		76
8d	NH ₂	2-Pyridylmethyl		88
8e	NH ₂	4-Fluorobenzoyl		82
8f	NH ₂	Piperidylethyl		87
8g	NHCH ₃	Benzyl		89
8h	CH ₃	4-Fluorobenzyl		66
9a	NH ₂	4-Fluorobenzyl	3,4-Difluorophenyl	35
9b	NH ₂	4-Phenylbenzyl	Ethoxy	38
9c	NH ₂	3,5-Dimethoxybenzyl	Ethoxy	52
9d	NH ₂	2-Pyridylmethyl	Ethoxy	30
9e	NH ₂	4-Fluorobenzoyl	Ethoxy	28
9f	NH ₂	Piperidylethyl	Ethoxy	32
9g	NHCH ₃	Benzyl	3,5-Difluorobenzyl	8
9h	CH ₃	4-Fluorobenzyl	Ethoxy	84
10a	NH ₂	4-Fluorobenzyl	3,4-Difluorobenzyl	30
10b	NH ₂	4-Phenylbenzyl	Ethoxy	88
10c	NH ₂	3,5-Dimethoxybenzyl	Ethoxy	18
10d	CH ₃	4-Fluorobenzyl	Ethoxy	25

[a] Isolated yield.

sulfur atom is envisioned to hinder the possible formation of azaquinone metabolites like **3a**. Compounds **9b–9g** and compounds **10b–10c** have other rings or different substitution patterns in place of the 4-fluorobenzyl group (Table 1). Compounds **9g–9h** and **10d**, on the other hand, have a methyl or methyl amine moiety instead of a primary amine. This modification, owing to the absence of primary amine, may result in analogues with little tendency to form metabolites like **3b**. In addition, the ethyl carbamate of **1** was replaced with fluoro-substituted phenyl or benzyl groups to give compounds **9a**, **9g** and **10a**, respectively. The rationale for this bulky, lipophilic modification comes from the recent patent literature on this class of compounds.^[8]

In an initial test set of systematically alkylated flupirtine derivatives reported earlier, EC₅₀ values for their $K_V7.2/K_V7.3$ channel opening activity correlated with oxidation potentials.^[9] In order to evaluate this proposed connection, we followed a similar approach to increase stability towards oxidation. By replacement of the secondary amino group connecting the two aromatic moieties in **1** by a thioether or thioester group in **9a–h**, we aimed to alter the oxidation pathway of the molecule while retaining or even improving biological activity.

The synthesis of most of the compounds was commenced with the amination of 2,6-dichloro-3-nitropyridine yielding intermediates **6a** or **b** (Scheme 1). The only exceptions were the syntheses of compounds **7c**, **8h**, **9h** and **10d**, which instead started with 6-bromo-2-methyl-3-nitropyridine (**6c**). The halogen substituents in **6a–c** were unambiguously replaced by a thiol group. Subsequently, thioether analogues were synthesized by straightforward nucleophilic attack of the thiol group on reactants with different cyclic structures in β -position. Following the thioether synthesis, the 3-nitro group in **8a–h** was reduced to a primary amine with various classical reducing agents and then acylated to give the corresponding carbamate



Scheme 1. Synthesis of compounds **8a–h**, **9a–h** and **10a–d** (for residues R¹, R², R³ in **8a–10d** consult Table 1). a) for **6a**: aq. NH₃ (25%), 2-propanol, 35 °C, 5 days; for **6b**, methylamine, triethylamine, acetonitrile, 0 °C 10 min, then rt, 30 min; b) Na₂S · 9 H₂O, S₈, NaOH, ethanol, reflux, 3–6 h; c) for **8a–d** and **8f–h**: alkylating agents, aq. KOH (10%), DMF, rt, 1 h; for **8e**: 4-fluorobenzoyl chloride, triethylamine, 2-propanol, reflux, overnight; d) for **9b–f**, **9h**: SnCl₂ · 2 H₂O, absolute ethanol, 70 °C, argon, overnight - 48 h, then triethylamine, acylating agent, 40 °C, 3 h - overnight; for **9a**: iron powder, NH₄Cl, 4:1 ethanol/water, 100 °C, 1 h, then triethylamine, acylating agent, 0 °C, 1.5 h; for **9g**: iron powder, NH₄Cl, 4:1 ethanol/water, 100 °C, 2 h, then acylating agent, HATU, 40 °C, overnight e) *m*-chloroperbenzoic acid, dichloromethane, 0 °C, 2 h.

9b–f, and **h** or amide analogues **9a** and **g** in yields varying between 8 and 84%.

The important anthelmintic albendazole, belonging to chemical family of alkylarylthioethers, is rapidly oxidized to albendazole sulfoxide and subsequently to albendazole sulfone (not shown).^[11] Albendazole sulfoxide is considered to be the therapeutically active form of the drug, even so re-reduction inside the parasites contributes significantly to the mode of action. However, the role of albendazole metabolism for the toxicity in humans is unknown. In the case of **9a** and **b**, we similarly anticipate that the main reaction products of oxidation might be sulfoxides **10a** and **b**, respectively (Scheme 1). In order to investigate the toxicity of these putative metabolites along with their parent compounds, we prepared the sulfoxides **10a–d**. For sulfoxidation, sulfides **9a–d** were treated with almost a stoichiometric equivalent (1.1 equivalents) of *m*-chloroperbenzoic acid in an ice cold water bath as described.^[12]

After structural confirmation by NMR and MS experiments, the compounds were studied electrochemically by measuring the oxidation potential with cyclic voltammetry. K_v7.2/K_v7.3 channel opening activity were measured by a fluorescence-based cellular thallium flux assay as described previously.^[9] To assess for possible hepatotoxicity, the synthesized analogues were evaluated with both a transgenic mouse hepatocyte (TAMH) and human hepatoma (HEP-G2) cell line by using the MTT-assay.




Figure 3. Concentration-response curves of **1** (as maleate salt) and **9g** obtained with fluorescence-based thallium-flux K_v7.2/3 channel-opening assay; determined after 30 min exposure; data were normalized to control (1% DMSO); values are the mean ± SD (n ≥ 3); EC₅₀ values calculated from log(concentration)-response curves which fit a four-parameter logistic equation.

The closely related deazathio-flupirtine analogues **9a** and **b** are as active as the marketed drug **1**. The less similar compound **9g** is even markedly more potent and effective (Figure 3).

Thioester **9e** was inactive in the tested concentration range, which shows that a sulfide bridge is the much better bioisosteric surrogate for the amino bridge than a thioester in its thionoester form. The products of the chemical oxidation experiments demonstrated that formation of reactive diimines does not occur but instead the oxidative reactivity is shifted towards relatively benign S-oxidation, at least in the sulfide series, as was anticipated. Oxidation is generally hampered in comparison to **1**, as the anodic peak potentials (E_{pa}) are higher. The resulting oxidation products, namely sulfoxides and sulfones, are putative metabolites that could also form from metabolic oxidation. Therefore, their cell toxicity is of interest and selected derivatives (**10a–d**) were thus evaluated for *in vitro* hepatotoxicity in hepatocellular models with that use the TAMH and HEP-G2 cell lines.^[13]

Except for compounds **1**, **9a**, **c**, and **d**, LD₅₀ values after 24 h could not be determined due to a lack of aqueous solubility. To gain another quantitative indicator of toxicity, LD₂₅ values after 48 h, which could be determined at lower concentrations where water solubility was not an issue, were determined for the most promising compounds. The LD₂₅ for highly potent and effective **9g** is 6 ± 3 and 4 ± 4 μM in the TAMH and HEP-G2 cell lines, respectively, and thus considerably lower than for **1** (Table 2). However, this increase in cell toxicity is more than compensated by the superior K_v7.2/3 channel opening activity of **9g** compared to **1**, yielding better safety indices of 400 versus 112 and 267 versus 81 in the TAMH and HEP-G2 cell lines, respectively. Because **9g** has the highest logD_{7.4} within this series of compounds, lipophilicity but not oxidizability or resulting reactivity might be important for the underlying mechanisms of action and toxicity.

Based on these findings, we conclude that the development of thio-analogues of known drugs **1** and **2** may result in K_v7.2/7.3 channel openers with more favorable therapeutic indices than flupirtine. Because they do not form reactive oxidation products *in vitro* they could even help to separate structure-activity from structure-toxicity relationships.

Table 2. Anodic peak potentials (E_{pa}) of flupirtine (**1**) and derivatives **9a–h** and **10a–d**, EC_{50} and E_{max} values towards $K_v7.2/3$ channels in HEK293 cells and LD_{50} (24 h exposure) and LD_{25} values (48 h exposure) in TAMH cells and HEP-G2 cells as well as toxicity/activity ratios.

Entry	$E_{pa}^{[a]}$ [mV]	$\log D_{7.4}$	$EC_{50}^{[b]}$ [μ M]	E_{max} [%]	$LD_{50}^{[c]}$ [μ M]	$LD_{25}^{[c]}$ [μ M]	Tox./Act. ^[c]	$LD_{50}^{[d]}$ [μ M]	$LD_{25}^{[d]}$ [μ M]	Tox./Act. ^[d]
1	350	2.96	$0.918 \pm 0.099^{[e]}$	100	487 ± 51	103 ± 47	112	547 ± 111	74 ± 40	81
9a	442	3.90	0.26 ± 0.082	100 ± 23	> 30	13 ± 04	50	8 ± 3	4 ± 1	15
9b	452	4.34	0.253 ± 0.042	69 ± 9	> 63	14 ± 13	55	> 250	n.d. ^[f]	n.d. ^[f]
9c	450	3.61	> 10	–	> 250	n.d. ^[f]	n.d. ^[f]	134 ± 22	n.d. ^[f]	n.d. ^[f]
9d	499	2.62	> 10	–	> 1000	n.d. ^[f]	n.d. ^[f]	831 ± 149	n.d. ^[f]	n.d. ^[f]
9e	573	3.00	> 10	–	> 125	n.d. ^[f]	n.d. ^[f]	> 250	n.d. ^[f]	n.d. ^[f]
9f	573	2.04	> 10	–	> 500	n.d. ^[f]	n.d. ^[f]	> 500	n.d. ^[f]	n.d. ^[f]
9g	631	4.27	0.015 ± 0.002	147 ± 9	> 7.5	6 ± 03	400	> 10	4 ± 4	267
9h	855	3.85	0.269 ± 0.031	129 ± 3	> 10	> 10	–	> 30	25 ± 16	93
10a	628	3.24	> 10	–	> 100	n.d. ^[f]	n.d. ^[f]	> 125	n.d. ^[f]	n.d. ^[f]
10b	654	3.72	> 10	–	> 63	n.d. ^[f]	n.d. ^[f]	> 63	n.d. ^[f]	n.d. ^[f]
10c	442	2.81	> 10	–	> 500	n.d. ^[f]	n.d. ^[f]	> 500	n.d. ^[f]	n.d. ^[f]
10d	n.o. ^[g]	3.02	> 10	–	> 500	n.d. ^[f]	n.d. ^[f]	> 500	n.d. ^[f]	n.d. ^[f]

[a] Determined with 1.0 mM compound in 100 mM TRIS-buffer (pH 7.4); [b] EC_{50} - and LD_{50} -values are means and standard deviations of 4–5 independent determinations; [c] determined using TAMH cells; [d] determined using HEP-G2 cells; [e] flupirtine maleate salt was used; [f] not determined; [g] non-oxidizable.

Experimental Section

N-[6-(Benzylthio)-2-(methylamino)pyridin-3-yl]-2-(3,5-difluorophenyl)acetamide (**9g**)

Compound **8g** (2.8 mmol, 771 mg), iron powder (28 mmol, 1.57 g) and ammonium chloride (28 mmol, 1.5 g) were suspended in 15 mL ethanol 20%. The suspension was stirred at 100 °C for 2 hours, filtered over diatomaceous earth, and the filter washed with ethyl acetate. The filtrate was poured into water. The collected precipitate was washed with ethyl acetate. 2,6-Dichlorophenyl acetic acid (2.8 mmol, 600 mg) and *O*-(7-azabenzotriazole-1-yl)-*N,N,N',N'*-tetramethyluroniumhexafluorophosphate (HATU, 5.6 mmol, 2.1 g) were added and the mixture was stirred at 40 °C overnight. The product was separated using silica gel chromatography (solvent: ethyl acetate/hexane). The combined product containing fractions were evaporated to dryness. The residue was dissolved in ethanol and water was added to precipitate the product. Lavender colored solid (yield=8%); purity 100%; mp: 201–202 °C; 1H NMR (400 MHz, DMSO- d_6): δ =9.25 (s, 1H), 7.40 (m, 2H), 7.30 (m, 4H), 7.13 (m, 3H), 6.41 (d, J =7.8 Hz, 1H), 6.23 (d, J =4.6 Hz, 2H), 4.38 (s, 2H), 3.70 (s, 2H), 2.89 (d, J =4.6 Hz, 2H); ^{13}C NMR (100 MHz, DMSO- d_6): δ =168.7, 163.4 (dd, J =13 Hz, J =244 Hz, 2 C), 153.2, 151.6, 140.4 (t, J =10 Hz, 1 C), 138.9, 133.2, 128.6 (2 C), 128.3 (2 C), 126.8, 115.1, 112.7 (dd, J =6 Hz, J =17 Hz, 2 C), 107.9, 102.2 (t, J =26 Hz, 1 C), 41.8, 33.3, 27.9; IR: $\tilde{\nu}$ =3442, 3404, 3269, 1652, 1591, 1496, 1389, 1230, 1119, 991, 696 cm^{-1} ; HRMS-ESI m/z [M–H][–] calcd for $C_{14}H_{16}N_4O_2S$: 398.1144, found: 398.1157. For synthetic details of other compounds see supporting information.

Acknowledgements

AS is thankful for support for the article processing charge from the DFG (German Research Foundation, 393148499) and the Open Access Publication Fund of the University of Greifswald. CB was supported by DFG grant LI 765/7-1, KB by DFG BE 1287/6-1.

Conflict of Interest

The authors declare no conflict of interest.

Keywords: medicinal chemistry · ion channels · oxidation · structure-activity relationships · sulfides

- [1] C. Gomis-Perez, M. V. Soldovieri, C. Malo, P. Ambrosino, M. Tagliatela, P. Areso, A. Villarroel, *Front. Mol. Neurosci.* **2017**, *10*, 117.
- [2] E. Scheuch, K. Methling, P. J. Bednarski, S. Oswald, W. Siegmund, *J. Pharm. Biomed. Anal.* **2015**, *102*, 377–385.
- [3] A. Douros, E. Bronder, F. Andersohn, A. Klimpel, M. Thomae, H.-D. Orzechowski, R. Kreutz, E. Garbe, *Eur. J. Clin. Pharmacol.* **2014**, *70*, 453–459; and (Erratum) **2015**, *71*, 387.
- [4] a) D. Sampath, R. Valdez, A. W. White, Y. H. Raol, *Neuropharmacology* **2017**, *123*, 126–135; b) T. Zhang, M. S. Todorovic, J. Williamson, J. Kapur, *Ann. Clin. Transl. Neurol.* **2017**, *4*, 888–896.
- [5] T. Garin Shkolnik, H. Feuerman, E. Didkovsky, I. Kaplan, R. Bergman, L. Pavlovsky, E. Hodak, *JAMA Dermatol.* **2014**, *150*, 984–989.
- [6] a) W. Siegmund, C. Modeß, E. Scheuch, K. Methling, M. Keiser, A. Nassif, D. Roszkopf, P. J. Bednarski, J. Borlak, B. Terhaag, *Br. J. Clin. Pharmacol.* **2015**, *79*, 501–513; b) P. Nicoletti, A. N. Werk, A. Sawle, Y. Shen, T. J. Urban, S. A. Coulthard, E. S. Bjornsson, I. Cascorbi, A. Floratos, T. Stammschulte, U. Gundert-Remy, M. R. Nelson, G. P. Aithal, A. K. Daly, *Pharmacogenet. Genomics*, **2016**, *26*, 218–224.
- [7] a) DE 102018212006.4; b) C. Bock, K. Beirou, A. S. Surur, L. Schulig, A. Bodtke, P. J. Bednarski, A. Link, *Org. Biomol. Chem.* **2018**, *16*, 8695–8699.
- [8] C. Bock, A. Link, *Fut. Med. Chem.* **2019**, *11*, in press.
- [9] C. J. Lemmerhirt, M. Rombach, A. Bodtke, P. J. Bednarski and A. Link, *ChemMedChem*. **2015**, *10*, 368–379.
- [10] A. Bottoni, M. Calvaresi, A. Ciogli, B. Cosimelli, G. Mazzeo, L. Pissani, E. Severi, D. Spinelli, S. Superchi, *Adv. Synth. Catal.* **2013**, *355*, 191–202.
- [11] J. D. Turner, R. Sharma, G. Al Jayoussi, H. E. Tyrer, J. Gamble, L. Hayward, R. S. Priestley, E. A. Murphy, J. Davies, D. Waterhouse, D. A. N. Cook, R. H. Clare, A. Cassidy, A. Steven, K. L. Johnston, J. McCall, L. Ford, J. Hemingway, S. A. Ward, M. J. Taylor, *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E9712–E9721.
- [12] a) V. Barrese, F. Miceli, M. V. Soldovieri, P. Ambrosino, F. A. Iannotti, M. R. Cilio, M. Tagliatela, *Clin. Pharmacol.* **2010**, *2*, 225–236; b) A. S. Surur, L. Schulig, A. Link, *Arch. Pharm. Chem. Life Sci.* **2019**, *352*: e1800248.
- [13] a) A. Van Summeren, J. Renes, F. G. Bouwman, J.-P. Noben, J. H. M. van Delft, J. C. S. Kleinjans, E. C. M. Mariman, *Toxicol. Sci.* **2011**, *120*, 109–122; b) M. Davis, B. D. Stamper, *BioMed Res. Int.* **2016**, DOI: 10.1155/2016/4780872.

Manuscript received: November 6, 2018

Revised manuscript received: November 26, 2018

Version of record online: ■■■, ■■■■